Alnylam Pharmaceuticals: Oppenheimer cuts target price to $320 from $350
ALNY•Oppenheimer cut its target price for Alnylam Pharmaceuticals to $320 from $350.
Related News
Moleculin Biotech completes dosing in Part A of Miracle trial; data readout on track for Q1 2027
MBRX•
Vor Biopharma enters sales agreement with William Blair and RBC Capital Markets
VOR•
Yen gains after BOJ; AI selloff weighs on dollar
TLT•
Central Puerto buys back shares worth AR$ 198 million
CEPU•
Standard Motor Products’ nine-month 2026 GAAP earnings from continuing operations rise 18% to $82.7 million
SMP•